Opinion|Videos|June 5, 2024
Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma
The key opinion leaders explore the utilization of biomarkers in guiding the treatment of severe or uncontrolled asthma, discussing the specific role of eosinophils in informing therapeutic decision-making for patients with challenging asthma cases.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Which biomarkers do you use to guide treatment of severe or uncontrolled asthma?
- What factors can change eosinophil levels?
- How often are these factors considered when treating asthma?
Advertisement
Related to this article
Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.
APPs described earlier recognition of type 2 disease, documentation strategies for payers, and the role of specialty pharmacy in biologic access.
Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD.
Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI
5